Category: Lung Cancer Genetics and Genomics

Check Out the January 2018 Edition of our newsletter

Want to know more about what we are doing at ALCF? Read our most recent newsletter to see our 2017 year in review, meet our new partner, IASLC, learn how you can get involved in our immunotherapy study, participate in a fun new way to raise funds through social sharing called the Your Cancer Game… Read More

Posted by ALCF Staff on February 1st, 2018

Check Out the October 2017 Edition of our newsletter

Want to know more about what we are doing at ALCF? Read our most recent newsletter and learn more about Lung Cancer Awareness Month, our new #ShowUsYourMug campaign, how we are teaming up with Boehringer Ingelheim to make the holiday season a little brighter for lung cancer patients and their families, and more. Click here… Read More

Posted by ALCF Staff on November 1st, 2017

Check Out the September 2017 Edition of our newsletter

Want to know more about what we are doing at ALCF? Read our most recent newsletter and learn more about our thoughts on healthcare reform, crowdsourcing in cancer, a new study from ALCMI and Inivata, an interview with Bonnie, upcoming events, and more. Click here to read the newsletter now

Posted by ALCF Staff on October 2nd, 2017

Patient Advocacy Strategies Evolve as Genomic Advances Change Understanding of Cancer

The ROS1ders, are throwing their energy behind creating preclinical mouse models and cells lines that will inform drug development efforts and improve understanding… Read More

Posted by ALCF Staff on September 8th, 2017

Do you know a ROS1-fusion positive cancer patient?

In May, 2016, the Bonnie J. Addario Lung Cancer Foundation launched the Global ROS1 Initiative, in partnership with cancer patients whose tumors are driven by ROS1 gene fusions. These ROS1 gene fusions are abnormal changes in cells that drive the growth and spread of several different cancer types such as non-small cell lung, gastric, ovarian,… Read More

Posted by Dr. Guneet Walia on February 23rd, 2017

New Lung Cancer Registry Launched Today

The Bonnie J. Addario Lung Cancer Foundation (ALCF), the American Lung Association (ALA) and AltaVoice (formerly known as PatientCrossroads) today announced the new Lung Cancer Registry. The Registry is a place to gather and store detailed information for patients with lung cancer, which kills more Americans each year than the next three most frequent types… Read More

Posted by ALCF Staff on November 4th, 2016

Liquid Biopsy Test Approved by the FDA for EGFR+ Lung Cancer

On June 1, 2016 the US Food and Drug Administration (FDA) approved the first ever blood test to aid clinical decision making for targeted therapies for lung cancer. This blood test, a companion diagnostic called Cobas EGFR Mutation Test v2, allows the detection of mutations in the EGFR (Epidermal Growth Factor Receptor) gene, such as… Read More

Posted by Dr. Guneet Walia on September 29th, 2016

Lung Cancer Updates from ASCO 2016

Download PDF of this post What is ASCO? ASCO is the American Society of Clinical Oncology that has an annual meeting each year where key research and clinical medicine highlights are presented by cancer researchers & clinicians to the global community. This was the 52nd Annual Meeting of the American Society of Clinical Oncology, held… Read More

Posted by Dr. Guneet Walia on July 20th, 2016

New Clinical Trial Available for ALK+ NSCLC patients- XALT2

If you have non-small cell lung cancer (NSCLC), you may be interested in learning more about a clinical research study opportunity. Non-small cell lung cancer (NSCLC) is one of two types of lung cancer (the other is small cell lung cancer). Most lung cancers are NSCLC. Of the people who have NSCLC, only 3 percent… Read More

Posted by Danielle Hicks on April 1st, 2016

New Clinical Trial For Patients No Longer Benefitting from Standard Therapy, or For Whom No Standard Therapy is Available

This Monday, the American Society of Clinical Oncology (ASCO) launched its first ever clinical trial that has been designed with a unique format and allows patients with advanced solid tumor (including lung cancer), multiple myeloma, or B cell non-Hodgkin lymphoma who are no longer benefitting from standard anti-cancer treatments, or for whom no acceptable standard… Read More

Posted by Dr. Guneet Walia on March 23rd, 2016